Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 7/20 | 0.61 |
| ▸ | HTR1A | P08908 | 5/20 | 0.59 |
| ▸ | HTR2A | P28223 | 5/20 | 0.59 |
| ▸ | HTR2B | P41595 | 4/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.59 |
| ▸ | HTR1D | P28221 | 4/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HTR1B | P28222 | 2/20 | 0.59 |
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29945167 | 1.00 | NPSR1 (0.62) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| SCHEMBL11339569 | 0.83 | HTR2C (0.64) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| Serotonin SCHEMBL7805171 | 0.83 | NPSR1 (0.68) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| SCHEMBL266613 | 0.81 | NPSR1 (0.68) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| SCHEMBL5424801 | 0.80 | HTR2C (0.71) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| SCHEMBL9912222 | 0.80 | GPR84 (0.67) | HTR2CHTR1AHTR2AHTR2BHTR1D | |
| SCHEMBL5793206 | 0.80 | GPR84 (0.67) | TSHRHTR2CHTR1AHTR2ASLC6A4 | |
| SCHEMBL27821134 | 0.80 | GPR84 (0.67) | TSHRLMNAHTR2CHTR1AHTR2A | |
| SCHEMBL28534064 | 0.79 | HTR2C (0.74) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 | |
| Serotonin SCHEMBL29164900 | 0.78 | HTR2C (0.85) | NPSR1ALDH1A1CYP2C9TSHRNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| CN-118688333-A | Marker related to allergic rhinitis and kit thereof | 厦门市迈理奥科技有限公司 | 2024-09-24 | — | — | CN | claimed |
| EP-2164500-B1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2013-12-04 | — | — | EP | claimed |
| EP-2473199-A1 | ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS | Brain Watch Ltd. (IL) | 2012-07-11 | — | — | EP | claimed |
| US-20120156139-A1 | ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEROF FOR DIAGNOSING CONDITIONS AND DISORDERS | BRAIN WATCH LTD. (IL) | 2012-06-21 | — | — | US | claimed |
| US-20110300142-A1 | USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | IDOGEN AB (SE) | 2011-12-08 | — | — | US | claimed |
| WO-2011024156-A1 | ISOTOPICALLY LABELED NEUROCHEMICAL AGENTS AND USES THEREOF FOR DIAGNOSING CONDITIONS AND DISORDERS | BRAIN WATCH LTD. (IL) | 2011-03-03 | — | — | WO | claimed |
| EP-2164500-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | Idogen AB (SE) | 2010-03-24 | — | — | EP | claimed |
| WO-2008147283-A1 | THE USE OF ZEBURALINE FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR IMMUNE REJECTION OF TRANSPLANTS | SALFORD LEIF (SE) | 2008-12-04 | — | — | WO | claimed |
| US-20080287774-A1 | Magnetic Resonance Imaging and Spectroscopy Means and Methods Thereof | BRAIN WATCH LTD. (IL) | 2008-11-20 | — | — | US | claimed |
| US-7368434-B2 | Compounds useful for the inhibition of ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2008-05-06 | — | — | US | claimed |
| US-20070270332-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | VALLEE BERT L | 2007-11-22 | — | — | US | claimed |
| EP-1077697-B1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2006-07-19 | — | — | EP | claimed |
| EP-1645272-A2 | Daidzin derivatives for the treatment of alcohol dependence or alcohol abuse | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| CN-1671373-A | Compounds for inhibiting ALDH | ENDOWMENT FOR RES IN HUMAN BIO (US) | 2005-09-21 | — | — | CN | claimed |
| EP-1542675-A1 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | The Endowment For Research In Human Biology, Inc. (US) | 2005-06-22 | — | — | EP | claimed |
| US-20040068003-A1 | Compounds useful for the inhibition of ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC, | 2004-04-08 | — | — | US | claimed |
| WO-2004002470-A1 | COMPOUNDS USEFUL FOR THE INHIBITION OF ALDH | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2004-01-08 | — | — | WO | claimed |
| EP-1077697-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058124-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | THE ENDOWMENT FOR RESEARCH IN HUMAN BIOLOGY, INC. (US) | 1999-11-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270332-A1 | METHODS AND ASSAYS USEFUL IN THE TREATMENT OF ALCOHOL DEPENDENCE OR ALCOHOL ABUSE | ADH1A, ADH5, ADH1C | NPSR1 982/4885ALDH1A1 23/4885CYP2C9 1334/4885 |
| US-20040068003-A1 | Compounds useful for the inhibition of ALDH | ALDH2, ALDH1A1, ALDH3A1 | NPSR1 1000/4885ALDH1A1 2/4885CYP2C9 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.